Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL244918 | 0.91 | KMT2A (0.42) | MTNR1AMTNR1BKMT2ALMNASMN1; SMN2 | |
| SCHEMBL27677191 | 0.90 | KMT2A (0.41) | MTNR1AMTNR1BKMT2ALMNASMN1; SMN2 | |
| Water SCHEMBL20853621 | 0.88 | KMT2A (0.41) | MTNR1AMTNR1BKMT2ALMNASMN1; SMN2 | |
| SCHEMBL5587045 | 0.88 | KMT2A (0.42) | MTNR1AMTNR1BKMT2ALMNASMN1; SMN2 | |
| SCHEMBL1823998 | 0.86 | THRB (0.44) | SMN1; SMN2HTTALDH1A1MAPT | |
| SCHEMBL5586997 | 0.83 | THRB (0.44) | KMT2AHTTALDH1A1MAPT | |
| SCHEMBL28590884 | 0.82 | THRB (0.43) | KMT2AHTTALDH1A1MAPT | |
| SCHEMBL28604711 | 0.82 | THRB (0.43) | KMT2AHTTALDH1A1MAPT | |
| SCHEMBL2498356 | 0.81 | MTNR1A (0.59) | MTNR1AMTNR1BKMT2ALMNASMN1; SMN2 | |
| SCHEMBL917492 | 0.79 | GAA (0.59) | KMT2ASMN1; SMN2MEN1SLC2A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122011124-A | GLP-1R/GIPR/GCGR triple receptor agonist and application thereof | 上海生物制品研究所有限责任公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122011123-A | GLP-1R/GIPR/GCGR triple receptor agonist and application thereof | 上海生物制品研究所有限责任公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125737-A1 | REAGENT COMPOSITION AND KIT | DENKA COMPANY LIMITED (JP) | 2026-05-07 | — | — | US | disclosed |
| EP-4328320-B1 | REAGENT COMPOSITION AND KIT | DENKA COMPANY LTD (JP) | 2026-04-29 | — | — | EP | disclosed |
| US-20260076918-A1 | HETEROTELECHELIC COMPOUNDS | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2026-03-19 | — | — | US | disclosed |
| US-20250388544-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | VIVORYON THERAPEUTICS N.V. (DE) | 2025-12-25 | — | — | US | disclosed |
| WO-2025224169-A1 | DOSE REGIMENS FOR THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | VIVORYON THERAPEUTICS N.V. (DE) | 2025-10-30 | — | — | WO | disclosed |
| WO-2025224179-A1 | GLUTAMINYL CYCLASE INHBITORS FOR USE IN THE TREATMENT OF KIDNEY DISEASE | VIVORYON THERAPEUTICS N.V. (DE) | 2025-10-30 | — | — | WO | disclosed |
| US-20250327111-A1 | REAGENT COMPOSITION AND KIT | DENKA COMPANY LIMITED (JP) | 2025-10-23 | — | — | US | disclosed |
| US-12378186-B2 | Inhibitors of meprin α and β | VIVORYON THERAPEUTICS N.V. (DE) | 2025-08-05 | — | — | US | disclosed |
| US-20220299535-A1 | METHOD AND KIT FOR QUANTIFICATION OF SMALL, DENSE LDL CHOLESTEROL | DENKA COMPANY LIMITED (JP) | 2022-09-22 | — | — | US | disclosed |
| EP-4029949-A1 | KIT AND METHOD | Denka Company Limited (JP) | 2022-07-20 | — | — | EP | disclosed |
| EP-4029948-A1 | METHOD AND KIT FOR QUANTIFYING SMALL, DENSE LDL CHOLESTEROL | Denka Company Limited (JP) | 2022-07-20 | — | — | EP | disclosed |
| CN-114544924-A | Application of glyceride in disease prediction | 中国科学院上海营养与健康研究所 | 2022-05-27 | — | — | CN | disclosed |
| EP-3986868-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | Vivoryon Therapeutics N.V. (DE) | 2022-04-27 | — | — | EP | disclosed |
| CN-114364810-A | Method and kit for quantifying small, dense LDL cholesterol | 电化株式会社 | 2022-04-15 | — | — | CN | disclosed |
| CN-114364809-A | Kits and methods | 电化株式会社 | 2022-04-15 | — | — | CN | disclosed |
| EP-3967679-A1 | NOVEL INHIBITORS OF MEPRIN ALPHA AND BETA | Vivoryon Therapeutics AG (DE) | 2022-03-16 | — | — | EP | disclosed |
| US-8158375-B2 | Polymer and method of measuring cholesterol therewith | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2012-04-17 | — | — | US | disclosed |
| US-20090215097-A1 | Novel Polymer and Method of Measuring Cholesterol Therewith | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076918-A1 | HETEROTELECHELIC COMPOUNDS | LDLR, MSR1, LPAR2 | MTNR1A 207/4885MTNR1B 411/4885KMT2A 2449/4885 |
| US-20250388544-A1 | HETEROAROMATIC INHIBITORS OF ASTACIN PROTEINASES | BMP1, BMPR1A, BMPR1B | MTNR1A 498/4885MTNR1B 491/4885KMT2A 4184/4885 |
| US-20260125737-A1 | REAGENT COMPOSITION AND KIT | LIPA, LIPC, CETP | MTNR1A 4757/4885MTNR1B 4732/4885KMT2A 2659/4885 |
| US-12378186-B2 | Inhibitors of meprin α and β | MEP1A, MEP1B, CAPRIN1 | MTNR1A 2780/4885MTNR1B 2725/4885KMT2A 3359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.